David A.DeckerMDFACP

PubMed

• 3 citations
  Obesity and NonAdherence Correlate with Elevated Serum Estradiol Levels in Postmenopausal Women Receiving Adjuvant Aromatase Inhibitor Therapy
  David A. Decker, Robert B. Reynolds, David C Molthrop, Elizabeth Griffith, Tiffany Encarnacion
  The Breast Journal. 2014-09-01
• 86 citations
  Effects of Vaginal Estrogens on Serum Estradiol Levels in Postmenopausal Breast Cancer Survivors and Women at Risk of Breast Cancer Taking an Aromatase Inhibitor or a ...
  S. M. Wills, Anita Ravipati, Padmaja Venuturumilli, Cynthia Kresge, Elizabeth Folkerd
  Journal of Oncology Practice. 2012-02-07
• 23 citations
  Tamoxifen malabsorption after Roux-en-Y gastric bypass surgery: case series and review of the literature.
  S. M. Wills, Richard Philip Zekman, Daniel J. Bestul, Nafisa Kuwajerwala, David A. Decker
  Pharmacotherapy. 2010-02-01

Journal Articles

• Efffects of vaginal estrogens on serum estradiol levels in postmenopausal breast cancer survivors and women at risk of breast cancer taking an aromatase inhibitor or a...  
  Wills S, Ravipati A, Venuturumilli P, Kresge C, Folkerd E, Dowsett M, Hayes D, Decker D, J Oncol Prac, 1/1/2012
• Developing a nanoparticle test for prostate cancer scoring  
  Huo Q, Litherland SA, Sullivan S, Hallquist H, Decker DA, Rivera-Ramirez I, J Transl Med, 1/1/2012
• Toward an integrated knowledge environment to support modern oncology  
  Blake PM, Decker DA, Glennon TM, Liang YM, Losko S, Navin N, et al, Cancer J, 1/1/2011
• Tamoxifen malabsorption after Roux-en-Y gastric bypass surgery: case series and review of the literature  
  Wills SM, Zekman R, Bestul D, Kuwajerwala N, Decker D, Pharmacotherapy, 1/1/2010
• Managing symptoms among patients with breast cancer during chemotherapy: results of a two-arm behavioral trial  
  Given CW, Sikorskii A, Tamkus D, Given B, You M, McCorkle R, Champion V, Decker D, J Clin Oncol, 1/1/2008
• Establishing mild, moderate, and severe scores for cancer-related symptoms: how consistent and clinically meaningful are interference-based severity cut-points?  
  Given B, Given CW, Sikorskii A, Jeon S, McCorkle R, Champion V, Decker D, J Pain Symptom Manage, 1/1/2008
• Symptom management for cancer patients: a trial comparing two multimodal interventions  
  Sikorskii A, Given CW, Given B, Jeon S, Decker V, Decker D, Champion V, J Pain Symptom Manage, 1/1/2007
• Telephone contacts between triage nurses and cancer patients: An integral part of a community oncology practice  
  Lucia VC, Decker VB, Israel CE, Decker DA, Community Oncology, 1/1/2007
• Molecular classification system identifies invasive breast carcinoma patients who are most likely and those who are least likely to achieve a complete pathologic respo...  
  Goldstein NS, Decker D, Severson D, Schell S, Vicini F, Margolis J, et al, Cancer, 1/1/2007
• Study of sexual functioning determinants in breast cancer survivors  
  Speer JJ, Hillenberg B, Sugrue DP, Blacker C, Kresge CL, Decker VB, Zakalik D, Decker DA, Breast J, 1/1/2005
• Changes in management techniques and patterns of disease recurrence over time in patients with breast carcinoma treated with breast-conserving therapy at a single inst...  
  Pass H, Vicini FA, Kestin LL, Goldstein NS, Decker D, Pettinga J, Ingold J, Benitez P, Neuman K, Rebner M, Dekhne N, Martinez A, Cancer, 1/1/2004
• Estrogen replacement therapy in breast cancer survivors: a matched-controlled series  
  Decker DA, Pettinga JE, VanderVelde N, Huang RR, Kestin L, Burdakin JH, Menopause, 1/1/2003
• Acute and subacute toxicity associated with concurrent adjuvant radiation therapy and paclitaxel in primary breast cance therapy  
  Hana YM, Baglan L, Stromberg JS, Vicini FV, Decker DA, The Breast J, 1/1/2002
• Myelodysplastic syndrome at a large tertiary care community hospital: analysis according to the international prognostic scoring system  
  Jaiyesimi IA, Friedline JA, Mattson JC, Gyorfi T, Davis BH, Balasubramaniam M, Al-Khalili A, Burdakin J, Decker D, Zakalik C, Neumann K, Wilner F, Leuk Res, 1/1/2000
• Detection of circulating epithelial cells after surgery for benign breast disease  
  Crisan D, Ruark DS, Decker DA, Drevon AM, Dicarlo RG, Mol Diagn, 1/1/2000
• Impact of clinical, pathologic, and treatment-related factors on outcome in patients with locally advanced breast cancer treated with multimodality therapy  
  Victor SJ, Horwitz EM, Kini VR, Martinez AA, Pettinga JE, Dmuchowski CF, Decker DA, Wilner FM, Vicini FA, Am J Clin Oncol, 1/1/1999
• Hormone replacement therapy in breast cancer survivors  
  Decker DA, Pettinga JE, Cox TC, Burdakin JH, Jaiyesimi IA, Benitez PR, The Breast J, 1/1/1997
• Separate clones in concomitant multiple myeloma and a second B-cell neoplasm demonstrated by molecular and immunophenotypic analysis  
  Novak PM, Mattson JC, Crisan D, Chen J, Poulik MD, Decker D, Eur J Haematol, 1/1/1995
• Fractionation of Cremophor EL delineates components responsible for plasma lipoprotein alterations and multidrug resistance reversal  
  Kessel D, Woodburn K, Decker D, Sykes E, Oncol Res, 1/1/1995
• Use of tamoxifen for breast cancer: twenty-eight years later  
  Jaiyesimi IA, Buzdar AU, Decker DA, Hortobagyi GN, J Clin Oncol, 1/1/1995
• Immunohistochemical analysis of P-glycoprotein expression in breast cancer: clinical correlations  
  Decker DA, Morris LW, Levine AJ, Pettinga JE, Grudzien JL, Farkas DH, Ann Clin Lab Sci, 1/1/1995
• Effects of Cremophor EL on distribution of Taxol to serum lipoproteins  
  Sykes E, Woodburn K, Decker D, Kessel D, Br J Cancer, 1/1/1994
• Clinical problem solving using Bcl-2 and Bcr gene rearrangement analysis  
  Mattson JC, Crisan D, Wilner F, Decker D, Burdakin J, Laboratory Medicine, 1/1/1994
• Multidrug resistance phenotype (MDR)-a potential markder of chemotherpay risistance in breast cancer?  
  Decker DA, Morris LW, Levine AL, Pettinga JA, Grudzien JL, Farkes DH, Laboratory Medicine, 1/1/1993
• Prophylactic mastectomy for familial breast cancer  
  Decker D, JAMA, 1/1/1993
• Join now to see all

Books/Book Chapters

• Endrocrine Therapies in Breast Cancer 
  Chapter: Combined endocrine and chemotherapy in breast cancer 
  Jaiyesimi I, Wills S, Zekman R, Decker D, Buzdar AOxford University Press2007
• The Year Book of Obstetrics, Gynecology, and Women’s Health 
  Chapter: Hormone replacement therapy (HRT) in breast cancer survivors 
  Page 489 - 491Decker DA, Pettinga JE, Cox TC, Burdakin JH, Jaiyesimi IA, Benitez PRMosby1998
• Tumor Progression 
  Chapter: Complete responders to chemotherapy in metastatic breast cancer. Characterization and analysis 
  Page 223 - 243Decker DA., Ahmann, DL, Bisel, HF, Edmonson JH, Hahn RG, O'Fallen JREditors: R.G. Crispen.Elsevier, North Holland1980

Abstracts/Posters

• Predicting length of survival for adult outpatient oncology patients using clinic visit data
  Brown LE, Decker B, Decker DA, Americian Society of Clinical Oncology, Chicago, IL, 6/2/2012
• Comprehensive management of sexual dysfunction in breast cancer survivors
  D’Angelo KM, Wills S, Nancarrow-Tull J, Thomas V, Decker VB, Decker DA, Oncology Nursing Society, San Diego, CA, 5/13/2010
• Breast cancer patients reported sexual dysfunction: Nurse Clinician actions in an outpatient setting
  D’Angelo KM, Wills S, Nancarrow-Tull J, Thomas V, Decker VB, Decker DA, American Psychological Social Oncology Society, New Orleans, LA, 2/17/2010
• Effects of vaginal estrogens on serum estradiol levels in postmenopausal breast cancer survivors Taking an aromatase inhibitor or a selective estrogen receptor modulator
  Wills S, Ravipati, Venuturumilli P, Kresge C, Folkerd E, Dowsett M, Hayes D, Decker D, 32nd San Antonio Breast Cancer Symposium, 12/12/2009
• Scalp hypothermia minimizes alopecia in breast cancer patients receiving non-Anthracycline adjuvant chemotherapy
  Wills S, Ravipati A, Nguyen M, Zakalick D, Jaiyesimi I, Margolis J, Decker D, 32nd San Antonio Breast Cancer Symposium, 12/12/2009
• The effect of vaginal estrogens on plasma estradiol levels in women taking aromatase inhibitors
  Howard G, Wills S, Kresge C, McConnell D, Balasubramaniam M, Decker D, 30th San Antonio Breast Cancer Symposium, 12/14/2007
• Prognosis of T1bNOMO breast cancer inpatients receiving breast conservation therapy
  VanderVelde N, Decker D, Vicini F, Mitchell C, Haung R, Zakalik D, 24th Annual San Antonio Breast Cancer Symposium, 12/10/2001
• Consequences of estrogen replacement therapy (ERT) on breast density in breast cancer survivors treated with ERT and breast conservation
  Reddy M, Miller P, Furichia N, Song T, and Decker D, 24th Annual San Antonio Breast Cancer Symposium, 12/10/2001
• Estrogen replacement therapy (ERT) in breast cancer survivors
  Decker DA, Pettinga JE, Kestin L, Balasubramanian M, Vicini FA, Jaiyesimi IA, Benitez PR, Ruark D.S, Proc. ASCO, 5/21/2000
• Excessive toxicity concurrent adjuvant radiation therapy and paclitaxel in breast cancer
  Hanna YM, Baglan KL, Stromberg JS, Vicini FA, and Decker DA, 22nd Annual San Antonio Breast Cancer Symposium, 12/10/1999
• Detection of circulating epithelial cells after surgery for benign breast disease
  Crisan D, Ruark D, Decker D, Pettinga J, Alkhalili A, Camara A, Dicarlo R, XVII International and XIII European Congress of Clinical Chemistry and Laboratory Medicine, Firenze, Italy, 6/8/1999
• Lack of mammographic changes from hormone replacement therapy in women with breast conserving radiation
  Morris L, Decker DA, Pettinga J, Verhelle TE, Vicini F, Burdakin J, Jaiyesimi I, American Radium Society, New York, NY, 5/3/1997
• False-positive philadelphia chromosome in peripheral blood leukocytes
  Bharadwaj M, Al-Saadi A, Decker D, ACP and Michigan Society of Internal Medicine Meeting, Grand Traverse Village, MI, 9/19/1996
• Hormone replacement therapy (HRT) in breast cancer survivors
  Decker D, Cox T, Burdakin J, Jaiyesimi I, Pettinga J, Benitez P, 9th International Congress on Breast Diseases of the Senologic International Society (SIS), San Antonio, TX, 4/28/1996
• Flow cytometry in node negative breast cancer: Does this test alter adjuvant treatment decisions?
  Mohammed I, Decker D, Levine A, Hankin R, Pettinga J, 18th Annual San Antonio Breast Cancer Symposium, 12/10/1995
• Hormone replacement therapy in breast cancer survivors
  Cox T C, Decker D A, ACP and Michigan Society of Internal Medicine Meeting, Grand Traverse Village, MI, 9/22/1995
• Small cell cancer of prostate presenting with ectopic ACTH: Case report and review of literature
  Mohammed I, Decker D, ACP and Michigan Society of Internal Medicine Meeting, Grand Traverse Village, MI, 9/22/1995
• Relative nontoxic chemotherapy regimen for metastatic breast cancer
  Parikh RB, Decker DA, Burdakin JH, et al, 16th Annual San Antonio Breast Cancer Symposium, 11/5/1993
• Failure of Mdr1 (P-glycoprotein) by immunohistochemistry to identify a subset of patients with chemotherapy resistant breast cancer
  Decker DA, Morris LW, Levine JA, et al, 16th Annual San Antonio Breast Cancer Symposium, 11/5/1993
• Value of screening MUGA scans prior to receiving doxorubicin (DOX) chemotherapy
  Jaiyesimi I, Decker D, Wilner F, ACP and Michigan Society of Internal Medicine Meeting, Grand Traverse Village, MI, 9/26/1991
• Value of screening MUGA scans prior to receiving doxorubicin (DOX) chemotherapy
  Jaiyesimi I, Decker D, Wilner F, ASCO, Houston, TX, 5/20/1991
• Acquired inhibitor to Factor VIII in non-hemophilic patients
  Collins M, Wilner F, Neumann K, Decker DA, et al, ACP and Michigan Society of Internal Medicine Meeting, Grand Traverse Village, MI, 9/21/1989
• ProMACE-CytaBOM for treatment of NHL: A community hospital experience
  Magno M, Decker DA, Keenan J, ACP and Michigan Society of Internal Medicine Meeting, Grand Traverse Village, MI, 9/21/1989
• Lack of acute adriamycin associated cardiotoxicity in properly screened patients
  Cornett A, Decker DA, et al, ACP and Michigan Society of Internal Medicine Meeting, Grand Traverse Village, MI, 9/21/1989
• A tumor cell birth rate end-point that improves the predictability of xenograft assays for drug response of breast cancer patients
  Decker DA, Grudzien J, et al, 11th Annual San Antonio Breast Cancer Symposium, 11/29/1988
• Join now to see all

Lectures

• Consider Her Risk for Invasive Breast Cancer Evista 
  West Bloomfield, MI (2009; Bloomfield Hills, MI (2009); Grand Blanc, MI (2009); Cedar Rapids, IO (20 - 8/26/2010
• Avastin IRF Journal club/Herceptin Roundtable 
  Winston-Salem, NC - 8/5/2010
• Bevacizumab and Trastuzumab: Indications for the Treatment of Breast Cancer 
  Charlotte, NC - 7/29/2010
• Innovative Strategies for the Management of Patients with bone Metastases 
  Novartis, Troy, MI - 1/27/2010
• ASCO Review 
  Troy, MI - 9/14/2009
• Treatment of Breast Cancer with Bevacizumab and Trastuzumab 
  Genentech Canton, OH - 9/8/2009
• First Line Treatment of Metastatic Breast Cancer with Bevacizumab 
  Dayton, OH - 8/24/2009
• Personalized Health Care with Oncotype Dx for the Adjuvant Therapy of Breast Cancer 
  Southfield, MI - 1/22/2009
• San Antonio Breast Cancer Conference Review 
  Genentech Birmingham, MI - 1/19/2009
• Trastuzumab and Bevisumub Therapy for Breast Cancer 
  Genentech Avon, OH - 12/1/2008
• Letrozole and Zoledronic Acid Adjuvant Therapy of Breast Cancer 
  Genentech Grand Rapids, MI - 11/12/2008
• Adjuvant Hormonal Therapy of Breast Cancer 
  Novartis Grand Blanc, MI; Roanoke, IN - 5/15/2008
• Capecitabine in the Treatment of Breast Cancer 
  Roche, Saginaw, MI - 4/17/2008
• Trastuzumab Therapy for Breast Cancer 
  GenentechTroy, MI - 2/27/2008
• San Antonio Breast Cancer Symposium Review 
  AstraZenecaTroy, MI - 1/14/2008
• Optimizing Adjuvant Hormonal Therapy 
  Novartis Bloomfield Hills, MI; Novi, MI; Port Huron, MI; East Lansing, MI; Muncie, IN - 12/5/2007
• Arimidex for Postmenopausal Women with Early-Stage Hormone Receptor-Positive Breast Cancer 
  AstraZeneca East Lansing, MI - 11/13/2007
• Targeted Therapy with Trastuzumab for Breast Cancer 
  Genentech, Bixby Medical CenterAdrian, MI - 6/20/2007
• Adjuvant Treatment of HER2 Positive Node-Positive Breast Cancer 
  Genentech Troy, MI - 6/14/2007
• Trastuzumab for the Adjuvant Treatment of HER2-Positive Node-Positive Breast Cancer 
  Genentech Maumee, OH - 2/22/2007
• HER2-Targeted Therapy in the Treatment of Breast Cancer 
  Genentech Cleveland, OH - 11/8/2006
• Breast Cancer Update: Detection, Prevention, and New Therapeutic Considerations 
  Troy, MI - 10/25/2006
• Letrozole-Adjuvant Therapy of Breast Cancer 
  Novartis Troy, MI; Birmingham, MI; Jackson, MI; Grand Rapids, MI; Muskegon, MI - 4/18/2006
• Femara (Letrozole)-Adjuvant and Extended Adjuvant Therapy of Breast Cancer 
  Kalamazoo, MI (Oct 11, 2005); Grand Blanc, Michigan - 10/18/2005
• Current Hormonal Therapies for Postmenopausal Women with Early-Stage Hormone Receptor-Positive Breast Cancer 
  Petoskey, MI - 10/29/2004
• Join now to see all